The Medical launch landscape has shifted every year since 2021. 110 products indexed. Below, we break it down by volume, engagement, and the individual products that mattered most.
Five years of Medical launch data. Volume, engagement, and the products that stood out.
The Medical launch landscape has shifted every year since 2021. 110 products indexed. Below, we break it down by volume, engagement, and the individual products that mattered most.
| Quarter | Launches | Avg Interest Score | Top Product |
|---|---|---|---|
| Q1 2026 | 4 | 60 | TrumpRx |
| Q1 2025 | 10 | 73 | Cure AI |
| Q2 2025 | 4 | 87 | Pill Buddy: Cute meds tracker, reminders |
| Q3 2025 | 5 | 42 | Sully.ai |
| Q4 2025 | 3 | 112 | Claio.ai |
| Q1 2024 | 8 | 133 | PDF2Anki 3.0 |
| Q2 2024 | 5 | 60 | AI Patient Intake |
| Q3 2024 | 6 | 87 | Tubie |
| Q4 2024 | 4 | 187 | Doctronic AI + Human Doctors |
| Q1 2023 | 5 | 63 | MedGPT - AI Medication Guide |
| Q2 2023 | 7 | 124 | Skinive AI |
| Q3 2023 | 7 | 113 | Healsens |
| Q4 2023 | 11 | 104 | Docus.ai |
| Q1 2022 | 4 | 126 | Mage |
| Q2 2022 | 2 | 78 | Better P Kegel Workouts |
| Q3 2022 | 6 | 143 | Peachy Patients |
The Medical category has been steady over the past 6 years of tracked data. Total launches went from 15 in 2021 to 4 in 2026.
Average engagement ratio across all Medical launches: 0.26. Products above that line tend to solve a specific, painful problem. Products below it often entered a crowded space without clear differentiation.
Medical peaked in 2023 with 30 launches. That was 3 years ago. The decline since then could signal market consolidation, saturation, or attention shifting to adjacent categories.
Average engagement per product has held steady around 0.26 across the full dataset. The audience for Medical tools is consistent. Engagement doesn't rise or fall with volume, which suggests a stable base of interested users.
The highest-performing quarter was Q4 2024, with an average interest score of 187 across 4 launches. Doctronic AI + Human Doctors led that quarter.
53 B2B launches (48%) vs 57 B2C (52%) across the full Medical dataset. The split is close to even. Medical serves both business buyers and individual users.
2021: 15 launches. Average interest: 91. Average engagement: 0.24. Top launch: FirstIgnite (161 interest).
2022: 16 launches (+7% vs 2021). Average interest: 107. Average engagement: 0.26. Top launch: Peachy Patients (292 interest).
2023: 30 launches (+88% vs 2022). Average interest: 104. Average engagement: 0.25. Top launch: Skinive AI (434 interest).
2024: 23 launches (-23% vs 2023). Average interest: 114. Average engagement: 0.21. Top launch: Doctronic AI + Human Doctors (375 interest).
2025: 22 launches (-4% vs 2024). Average interest: 74. Average engagement: 0.36. Top launch: Cure AI (210 interest).
2026: 4 launches (-82% vs 2025). Average interest: 60. Average engagement: 0.24. Top launch: TrumpRx (111 interest).
Sum of all interest scores in the quarter divided by number of products. Simple average. We don't weight by category or product age.
Depends on what's declining. If volume drops but engagement rises, the market is maturing. That's often good for existing players. If both drop, the category may be dying. The quarterly breakdown on each page tells you which pattern you're seeing.
At least three. Two data points is a line, not a trend. We have five years of data for most categories, which is enough to distinguish real shifts from noise.
Current year launches compared to the same period last year. Positive means more products launching. Negative means the category cooled. Neither is inherently good or bad. A mature category with fewer but better launches is often healthier than one flooding the market with clones.
Launch volume drops but engagement per product rises. Fewer builders entering, but the ones that do find a more receptive audience. That's an opportunity signal. We flag it when we see it.
We report what happened. We don't predict. Five years of data shows patterns, but markets surprise people for a living.
Three common reasons. The market consolidated around winners. The technology matured and stopped generating new startups. Or builder attention shifted to adjacent categories. Usually it's a combination.